Page last updated: 2024-11-13

lys-pro-arg-arg-pro-tyr-vip(7-28)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(VIP-neurotensin) hybrid antagonist: contains fractions of VIP peptide & neurotensin; 28 amino acid sequence given in first source; consists of an N-terminal sequence from neurotensin and the 22 C-terminal amino acids of vasoactive intestinal peptide (VIP); inhibits VIP receptor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID102602038
MeSH IDM0188922

Synonyms (13)

Synonym
125093-93-8
(lys(1)-pro(2,5)-arg(3,4)-tyr(6))vip(7-28)
viphyb
vip-ne hybrid antag
vasoactive intestinal octacosapeptide (pig), 1-l-lysine-2-l-proline-3-l-arginine-4-l-arginine-5-l-proline-6-l-tyrosine-
neurotensin(6-11)vip(7-28)
lys-pro-arg-arg-pro-tyr-vip(7-28)
(vip-neurotensin) hybrid antagonist
lysyl-prolyl-arginyl-arginyl-prolyl-tyrosyl-vip(7-28)
vip antagonist
h-lys-pro-arg-arg-pro-tyr-thr-asp-asn-tyr-thr-arg-leu-arg-lys-gln-met-ala-val-lys-lys-tyr-leu-asn-ser-ile-leu-asn-nh2
mfcd00080365
h-lys-pro-arg-arg-pro-tyr-thr-asp-asn-tyr-thr-arg-leu-arg-lys-gln-met-ala-val-lys-lys-tyr-leu-asn-se

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In contrast, PHI was an effective stimulant in doses up to 15 nmol/rat but had no effect on either ACTH or CORT at a dose of 30 nmol/rat thus yielding a bell-shaped dose-response curve."( VIP antagonist demonstrates differences in VIP- and PHI-mediated stimulation and inhibition of ACTH and corticosterone secretion in rats.
Alexander, LD; Sander, LD, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (37.50)18.2507
2000's4 (25.00)29.6817
2010's6 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.69 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]